Browse Careers
Browse Investors

Bard Concludes Enrollment in Infection Control Endotracheal Tube Trial

MURRAY HILL, N.J.--(BUSINESS WIRE)--March 3, 2006--C. R. Bard, Inc. (NYSE:BCR) today announced that it has concluded enrollment in its respiratory infection control (RIC) endotracheal (ET) tube clinical trial. Based on Data Safety Monitoring Board review and input, the company believes that current trends in the data support the trial's secondary endpoint, the delayed onset of ventilator associated pneumonia (VAP). As a result, the company has decided to conclude enrollment in the study and to pursue 510(k) concurrence from the United States Food and Drug Administration (FDA) after trial follow-up is completed.

The trial is a prospective, multi-center, randomized, sequential design clinical study of the incidence and time to onset of VAP in patients who require mechanical ventilation. VAP is one of the most costly hospital acquired infections and has an associated mortality rate greater than 50 percent. It is especially prevalent in hospital intensive care units where patients are typically on an endotracheal tube for one to 10 days. The company's endotracheal tube incorporates its proprietary, silver-eluting technology. Subject to FDA concurrence, the company continues to anticipate launch of the product in the first half of 2007.

C. R. Bard, Inc. (www.crbard.com), headquartered in Murray Hill, N.J., is a leading multinational developer, manufacturer, and marketer of innovative, life-enhancing medical technologies in the fields of vascular, urology, oncology and surgical specialty products.

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management's current expectations, the accuracy of which is necessarily subject to risks and uncertainties. These statements are not historical in nature and use words such as "anticipate", "estimate", "expect", "project", "intend", "forecast", "plan", "believe", and other words of similar meaning in connection with any discussion of future operating or financial performance. Many factors may cause actual results to differ materially from anticipated results including product developments, sales efforts, income tax matters, the outcomes of contingencies such as legal proceedings, and other economic, business, competitive and regulatory factors. The company undertakes no obligation to update its forward-looking statements. Please refer to our December 31, 2005 10-K for more detailed information about these and other factors that may cause actual results to differ materially from those expressed or implied.

CONTACT: C. R. Bard, Inc.
Investor Relations:
Eric J. Shick, 908-277-8413
or
Media Relations:
Holly P. Glass, 571-243-1952

SOURCE: C. R. Bard, Inc.


bard-pubs

Primary Media Relations Contact

Scott Lowry
Vice President and Treasurer
C. R. Bard, Inc.
730 Central Avenue
Murray Hill, NJ 07974

Tel: 908-277-8365